Recordati Rare Diseases Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Recordati Rare Diseases Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11332
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Recordati Rare Diseases Inc (RRD), a subsidiary of Recordati SpA is a biopharmaceutical company that discovers and develops orphan drugs and biologics. The company’s products comprise chemet, neoprofen, panhematin, desoxyn, mustargen, carbaglu, cosmegen, peganone and tranxene, among others. It offers its products in the forms of capsules, injections and tablets. RRD’s products are used in the treatment of rare diseases such as acute intermittent porphyria, patent ductus arteriosus, Wilms’ tumor, NAGS deficiency, nonseminomatous testicular cancer, and others. The company markets its products through its distributors located across the US, Canada and others. RRD is headquartered in Lebanon, New Jersey, the US.

Recordati Rare Diseases Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Recordati Rare Diseases Acquires North American Rights to Cystadane 10
Partnerships 11
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 11
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 12
Recordati Rare Diseases Inc – Key Competitors 13
Recordati Rare Diseases Inc – Key Employees 14
Recordati Rare Diseases Inc – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Key Facts 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recordati Rare Diseases Acquires North American Rights to Cystadane 10
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 11
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 12
Recordati Rare Diseases Inc, Key Competitors 13
Recordati Rare Diseases Inc, Key Employees 14

List of Figures
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Recordati Rare Diseases Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sanofi India Ltd (SANOFI):企業の財務・戦略的SWOT分析
    Summary Sanofi India Ltd (Sanofi India), formerly Aventis Pharma Ltd, a subsidiary of Sanofi is a healthcare company that manufactures and markets pharmaceutical and prescription products. The company offers products in the form of capsules, tablets, insulin, injection, creams and gels, and solution …
  • RaQualia Pharma Inc (4579):製薬・医療:M&Aディール及び事業提携情報
    Summary RaQualia Pharma Inc (RaQualia) is a drug development company that discovers and develops pharmaceutical compounds. The company offers products such as anidulafungin, ziprasidone, dalbavancin, 5-HT2B antagonist, motilin receptor agonist, potassium-competitive acid blockerand 5-HT4 partial ago …
  • Athenex Inc (ATNX)-製薬・医療分野:企業M&A・提携分析
    Summary Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC is a drug manufacturing and distributing company that distributes therapies for cancer diseases and supportive therapies. The company offers drug discovery, drug formulation and clinical development. It offers products such as ointmen …
  • Boralex Inc (BLX):企業の財務・戦略的SWOT分析
    Boralex Inc (BLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Velatia SL:企業の戦略的SWOT分析
    Velatia SL - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Dicerna Pharmaceuticals Inc (DRNA)-製薬・医療分野:企業M&A・提携分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers therapies.The company discovers and develops treatments for rare inherited diseases including liver and for cancers that are genetically defined. Its pipeline product is being generated from the company’s propri …
  • Four Seasons Hotels Ltd:企業の戦略・SWOT・財務情報
    Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that utilizes and in-licenses technologies to develop new drugs. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05. Its SB01 drug is a new chemical entity …
  • Powerco Ltd:企業の戦略的SWOT分析
    Powerco Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Nexteer Automotive Group Ltd:企業の戦略・SWOT・財務情報
    Nexteer Automotive Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Nexteer Automotive Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Innate Pharma SA (IPH)-製薬・医療分野:企業M&A・提携分析
    Summary Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclo …
  • Stanwell Corp Ltd:企業の戦略的SWOT分析
    Stanwell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • DexTech Medical AB:製薬・医療:M&Aディール及び事業提携情報
    Summary DexTech Medical AB (DexTech) is a research company that conducts research in the areas of urological oncology, mainly within prostate cancer. The company develops product candidates based on a modified carbon hydrate molecule combined with active substances such as generics. Its technology p …
  • Dais Analytic Corps (DLYT):企業の財務・戦略的SWOT分析
    Summary Dais Analytic Corps (Dais) is an alternative energy company that provides industry changing and nano technology based applications. The company's products include ultra capacitors, clean water systems, heating and cooling equipment, among others. It also provides NanoAir, NanoCap, ConsERV an …
  • Business Connexion Group Limited:企業の戦略的SWOT分析
    Business Connexion Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Portola Pharmaceuticals Inc (PTLA):製薬・医療:M&Aディール及び事業提携情報
    Summary Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company which conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inh …
  • MedinCell SA (MEDCL):製薬・医療:M&Aディール及び事業提携情報
    Summary MedinCell SA (MedinCell) is a developer of therapeutic solutions for the healthcare market. The company develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. Its BEPO provides a controlled release of the …
  • ADOBE Inc (ADBE):企業の財務・戦略的SWOT分析
    ADOBE Inc (ADBE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Go-Ahead Group Plc:企業の戦略・SWOT・財務情報
    Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report Summary Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Farbest-Tallman Foods Corp.:企業の戦略・SWOT・財務分析
    Farbest-Tallman Foods Corp. - Strategy, SWOT and Corporate Finance Report Summary Farbest-Tallman Foods Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆